GlobeNewswire Inc | Apr 29, 2021 01:30AM EDT

April 29, 2021

Montrouge, France, April 29, 2021

DBV Technologies to Participate in Upcoming Investor Conferences

DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the following upcoming virtual investor conferences in May 2021.

KempenLife Sciences Conference, May 5, 2021 Dr. Pharis Mohideen, Chief Medical Officer, and Sebastien Robitaille, Chief Financial Officer, will participate in virtual investor meetings.

SocieteGeneraleNice Conference, May 27, 2021Daniel Tass, Chief Executive Officer, and Sebastien Robitaille, Chief Financial Officer, will participate in virtual investor meetings.

About DBV TechnologiesDBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT, DBVs method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBVs food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and North American operations in Summit, NJ. The Companys ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Companys ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact Anne PollakDBV Technologies+1 857-529-2363anne.pollak@dbv-technologies.com

Media ContactAngela MarcucciDBV Technologies+1646-842-2393angela.marcucci@dbv-technologies.com

Attachment

-- PDF Version